<DOC>
	<DOCNO>NCT01995071</DOCNO>
	<brief_summary>The purpose study evaluate safety antiviral effect multiple dose ABT-493 ABT-530 adult genotype 1 HCV .</brief_summary>
	<brief_title>A Study Evaluate Safety Antiviral Effect Multiple Doses ABT-493 ABT-530 Adults With Genotype 1 Hepatitis C Virus ( HCV )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Chronic HCV infection prior study enrollment . Screening laboratory result indicate HCV genotype 1infection . Subject plasma HCV RNA level great 10,000 IU/mL Screening . Per local standard , subject consider noncirrhotic compensate cirrhosis . History severe , lifethreatening significant sensitivity drug . Positive test result Hepatitis B surface antigen ( HBsAg ) antiHuman Immunodeficiency Virus antibody ( HIV Ab ) . Prior therapy treatment HCV . Any current past clinical evidence Child Pugh B C classification clinical history liver decompensation include ascites ( noted physical exam ) , variceal bleed hepatic encephalopathy . Any cause liver disease chronic HCV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Cirrhosis</keyword>
	<keyword>Child Pugh A</keyword>
	<keyword>Hepatitis C virus</keyword>
	<keyword>Compensated Cirrhosis</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Cirrhotic</keyword>
</DOC>